Program
tenofovir alafenamide
Also written as “E/C/F/TAF”, “TAF” and “B/F/TAF”.
Its studies are mostly in Acquired Immunodeficiency Syndrome · Hepatitis B, Chronic · HIV Infections · Hepatitis · Coinfection, led by 7 companies.
Drug pageTenofovir alafenamide: every studyMany companies study it; this page follows only the 61 they lead. All 140 studies, academic ones too, with its approvals and label.Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Gilead Sciencesits history only | 499 open or running | phase 4since Oct 23, 2023 | May 13, 2002 | Jun 2027phase 4 · NCT06337032 |
| Johnson & Johnsonits history only | 70 open or running | phase 3since Oct 17, 2014 | Oct 17, 2014 | none ahead |
| Henan Genuine Biotechits history only | 10 open or running | phase 1since May 13, 2025 | May 13, 2025 | none ahead |
| Humanis Saglık Anonim Sirketiits history only | 10 open or running | phase 1since Sep 9, 2024 | Sep 9, 2024 | none ahead |
| New Discoveryits history only | 10 open or running | phase 4since Dec 6, 2019 | Dec 6, 2019 | none ahead |
| The Crofoot Research Centerits history only | 10 open or running | phase 4since May 12, 2020 | May 12, 2020 | none ahead |
| Xiamen Amoytop Biotechits history only | 11 open or running | no phasesince Nov 24, 2024 | Nov 24, 2024 | May 31, 2029NCT06707922 |
Also a collaborator on its studies: Merck and F-star Therapeutics.
How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.
History and studies of every company. Pick one to see its own:
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 46 studies since Dec 14, 2011.
- Dec 6, 2019New Discovery’s first study: phase 4 study in Hepatitis B, ChronicNew to New DiscoveryNew Discovery · NCT04201808 · 100 enrolled · China
- Jan 21, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04236453 · 16 enrolled · Netherlands
- May 12, 2020The Crofoot Research Center’s first study: phase 4 study in Acquired Immunodeficiency SyndromeNew to The Crofoot Research CenterThe Crofoot Research Center · NCT04388904 · 75 enrolled · United States
- Dec 3, 2020Phase 1 study in HealthyJohnson & Johnson · NCT04661397 · 37 enrolled · Netherlands
- Aug 2, 2021Phase 3 study in Pre-Exposure Prophylaxis of HIV InfectionGilead Sciences · NCT04994509 · 5,368 enrolled · South Africa, Uganda
- Oct 23, 2023Phase 4 study in HIV-1-infectionGilead Sciences · NCT06104306 · 33 enrolled · United States, Canada, France
- Mar 22, 2024Phase 4 study in HIV-1-infectionGilead Sciences · NCT06337032 · 350 planned · Argentina, Panama, South Africa and more
- Sep 9, 2024Humanis Saglık Anonim Sirketi’s first study: phase 1 study in Chronic Hepatitis B in Adults and Paediatric PatientsNew to Humanis Saglık Anonim SirketiHumanis Saglık Anonim Sirketi · NCT06592300 · 42 enrolled · India
- Oct 4, 2024Phase 3 study in HIV-1-infectionGilead Sciences · NCT06630286 · 609 enrolled · United States, Argentina, Australia and more
- Nov 24, 2024Xiamen Amoytop Biotech’s first study: no phase study in Hepatitis B, ChronicNew to Xiamen Amoytop BiotechXiamen Amoytop Biotech · NCT06707922 · 350 planned · China
- May 13, 2025Henan Genuine Biotech’s first study: phase 1 study in HealthyNew to Henan Genuine BiotechHenan Genuine Biotech · NCT07002268 · 15 enrolled · China
- Jun 27, 2025Phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451 · 16 enrolled · United States, South Africa
- Jun 8, 2026Phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287 · 175 planned · United States, Australia, Canada and more
- Jul 13, 2026Phase 3 study in HIV-1-infectionGilead Sciences · NCT07708727 · 700 planned · United States, Canada, Germany and more
Ahead
- Jun 2027Primary completion: phase 4 study in HIV-1-infectionGilead Sciences · NCT06337032
- Aug 2027Primary completion: phase 2 study in HIV-1-infectionGilead Sciences · NCT07645287
- Mar 2028Primary completion: phase 1 study in HIV-1-infectionGilead Sciences · NCT07055451
- May 31, 2029Primary completion: no phase study in Hepatitis B, ChronicXiamen Amoytop Biotech · NCT06707922
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Human immunodeficiency virus type 1 reverse transcriptase inhibitor; Human immunodeficiency virus type 1 reverse transcriptase inhibitor”ChEMBL 37, by rule
Studies
The newest 60 of 61 led by companies developing it. Each opens its study page. Every study on its drug page →
| Study | Phase | Status | Led by | Primary completion | Size |
|---|---|---|---|---|---|
| NCT07708727HIV-1-infection · United States, Canada, Germany and more | 3 | Recruiting | Gilead Sciences | Oct 2030 | 700 |
| NCT07645287HIV-1-infection · United States, Australia, Canada and more | 2 | Recruiting | Gilead Sciences | Aug 2027 | 175 |
| NCT07055451HIV-1-infection · United States, South Africa | 1 | Active, not recruiting | Gilead Sciences | Mar 2028 | 16 |
| NCT07002268Healthy · China | 1 | Completed | Henan Genuine Biotech | May 4, 2022 | 15 |
| NCT06707922Hepatitis B, Chronic · China | – | By invitation | Xiamen Amoytop Biotech | May 31, 2029 | 350 |
| NCT06630286HIV-1-infection · United States, Argentina, Australia and more | 3 | Active, not recruiting | Gilead Sciences | Apr 17, 2026 | 609 |
| NCT06592300Chronic Hepatitis B in Adults and Paediatric Patients · India | 1 | Completed | Humanis Saglık Anonim Sirketi | Aug 2, 2024 | 42 |
| NCT06337032HIV-1-infection · Argentina, Panama, South Africa and more | 4 | Recruiting | Gilead Sciences | Jun 2027 | 350 |
| NCT06104306HIV-1-infection · United States, Canada, France | 4 | Completed | Gilead Sciences | Jan 29, 2025 | 33 |
| NCT04994509Pre-Exposure Prophylaxis of HIV Infection · South Africa, Uganda | 3 | Active, not recruiting | Gilead Sciences | May 27, 2024 | 5,368 |
| NCT04661397Healthy · Netherlands | 1 | Completed | Johnson & Johnson | Jul 2, 2021 | 37 |
| NCT04388904Acquired Immunodeficiency Syndrome · United States | 4 | Completed | The Crofoot Research Center | Apr 5, 2024 | 75 |
| NCT04236453Healthy · Netherlands | 1 | Terminated | Johnson & Johnson | Apr 10, 2020 | 16 |
| NCT04201808Hepatitis B, Chronic · China | 4 | UNKNOWN | New Discovery | Sep 30, 2023 | 100 |
| NCT04143594HIV-1-infection · United States, Dominican Republic, Puerto Rico | 2 | Completed | Gilead Sciences | Oct 5, 2021 | 183 |
| NCT03960645HIV-1-infection · United States, Dominican Republic, Thailand | 1 | Completed | Gilead Sciences | Jul 21, 2022 | 62 |
| NCT03739866HIV-1 Infection · United States | 1 | Completed | Gilead Sciences | Nov 14, 2019 | 53 |
| NCT03631732HIV-1 Infection · United States | 3 | Completed | Gilead Sciences | Aug 12, 2019 | 496 |
| NCT03547908HIV-1/HBV Co-Infection · United States, China, Dominican Republic and more | 3 | Completed | Gilead Sciences | Feb 25, 2022 | 244 |
| NCT03434353Hepatitis B, Chronic · Hong Kong, Korea, Republic of | 2 | Terminated | Gilead Sciences | Jan 20, 2020 | 123 |
| NCT03405935HIV-1 Infection · Belgium, France, Italy and more | 3 | Completed | Gilead Sciences | Nov 20, 2018 | 86 |
| NCT03180619Hepatitis B, Chronic · United States, Canada, Hong Kong and more | 2 | Completed | Gilead Sciences | Mar 27, 2019 | 124 |
| NCT03110380HIV-1-infection · United States, Austria, Canada and more | 3 | Completed | Gilead Sciences | Dec 4, 2018 | 567 |
| NCT02984852Healthy · United States | 1 | Completed | Johnson & Johnson | Feb 2017 | 30 |
| NCT02932150Hepatitis B, Chronic · United States, Belgium, Hong Kong and more | 2 | Active, not recruiting | Gilead Sciences | Oct 27, 2026 | 150 |
| NCT02881320HIV-1 Infection · United States, South Africa, Thailand and more | 3 | Active, not recruiting | Gilead Sciences | Mar 24, 2025 | 177 |
| NCT02862548Hepatitis B, Chronic · New Zealand | 2 | Completed | Gilead Sciences | Feb 8, 2018 | 51 |
| NCT02842086Pre-Exposure Prophylaxis of HIV-1 Infection · United States, Austria, Canada and more | 3 | Terminated | Gilead Sciences | Jan 31, 2019 | 5,399 |
| NCT02836249Hepatitis · China | 3 | Completed | Gilead Sciences | Mar 21, 2017 | 181 |
| NCT02836236Hepatitis · China | 3 | Completed | Gilead Sciences | Apr 5, 2017 | 155 |
| NCT02707601Hepatitis C · United States, Puerto Rico | 3 | Completed | Gilead Sciences | Sep 14, 2017 | 150 |
| NCT02652624HIV-1 Infection · United States, Dominican Republic, Puerto Rico and more | 3 | Completed | Gilead Sciences | Oct 9, 2017 | 472 |
| NCT02616029HIV-1 Infection · United States, France, Germany and more | 3 | Completed | Gilead Sciences | Oct 11, 2018 | 66 |
| NCT02616783HIV-1 Infection · Belgium, France, Italy and more | 3 | Completed | Gilead Sciences | Feb 21, 2018 | 167 |
| NCT02605954HIV-1 Infection · United States, France, Germany and more | 3 | Completed | Gilead Sciences | Jun 14, 2017 | 275 |
| NCT02607956HIV-1 Infection · United States, Australia, Belgium and more | 3 | Completed | Gilead Sciences | May 12, 2017 | 657 |
| NCT02600819Kidney Failure, Chronic · United States, Austria, France and more | 3 | Completed | Gilead Sciences | Sep 29, 2017 | 55 |
| NCT02578550Acquired Immunodeficiency Syndrome · Netherlands | 1 | Completed | Johnson & Johnson | Feb 2016 | 126 |
| NCT02475135Acquired Immunodeficiency Syndrome · Belgium | 1 | Completed | Johnson & Johnson | Aug 14, 2015 | 72 |
| NCT02469246HIV-1 Infection · United States, Belgium, Canada and more | 3 | Completed | Gilead Sciences | Dec 11, 2017 | 567 |
| NCT02431247Acquired Immunodeficiency Syndrome · United States, Belgium, Canada and more | 3 | Completed | Johnson & Johnson | Mar 2, 2017 | 725 |
| NCT02397694HIV-1 Infection · United States | 2 | Completed | Gilead Sciences | Nov 30, 2015 | 98 |
| NCT02296853Hepatitis B · United States, Germany, New Zealand | 1 | Completed | Gilead Sciences | Apr 17, 2015 | 20 |
| NCT02276612HIV · United States, South Africa | 3 | Completed | Gilead Sciences | Nov 10, 2016 | 60 |
| NCT02269917Acquired Immunodeficiency Syndrome · United States, Belgium, Canada and more | 3 | Completed | Johnson & Johnson | Feb 2017 | 1,149 |
| NCT02121795HIV-1 Infection · United States, Belgium, Canada and more | 3 | Completed | Gilead Sciences | Aug 12, 2015 | 668 |
| NCT02071082Coinfection · United States, Canada, Japan | 3 | Completed | Gilead Sciences | Jan 23, 2015 | 79 |
| NCT02016924Acquired Immunodeficiency Syndrome · United States, Argentina, South Africa and more | 3 | Active, not recruiting | Gilead Sciences | Jun 13, 2025 | 133 |
| NCT01967940HIV Infections · United States, Dominican Republic, Russian Federation and more | 3 | Completed | Gilead Sciences | May 21, 2015 | 55 |
| NCT01968551HIV Infections · United States, Canada | 3 | Completed | Gilead Sciences | Jul 21, 2015 | 158 |
| NCT01940471Hepatitis · United States, Australia, Bulgaria and more | 3 | Completed | Gilead Sciences | Nov 16, 2015 | 875 |
| NCT01940341Hepatitis · United States, Australia, Canada and more | 3 | Completed | Gilead Sciences | Sep 30, 2015 | 426 |
| NCT01854775Acquired Immunodeficiency Syndrome · United States, South Africa, Thailand and more | 3 | Completed | Gilead Sciences | May 11, 2020 | 129 |
| NCT01818596HIV Infections · United States, Australia, Dominican Republic and more | 3 | Completed | Gilead Sciences | Jul 31, 2014 | 252 |
| NCT01815736HIV Infections · United States, Australia, Austria and more | 3 | Completed | Gilead Sciences | Mar 16, 2015 | 1,443 |
| NCT01797445HIV Infections · United States, Canada, Dominican Republic and more | 3 | Completed | Gilead Sciences | Sep 19, 2014 | 872 |
| NCT01780506HIV Infections · United States, Australia, Austria and more | 3 | Completed | Gilead Sciences | Aug 26, 2014 | 872 |
| NCT01671787Hepatitis B, Chronic · United States, Australia, Canada and more | 1 | Completed | Gilead Sciences | Apr 2013 | 51 |
| NCT01565850Acquired Immunodeficiency Syndrome · United States, Puerto Rico | 2 | Completed | Gilead Sciences | Jan 2013 | 153 |
| NCT01497899Acquired Immunodeficiency Syndrome · United States, Puerto Rico | 2 | Completed | Gilead Sciences | Oct 17, 2012 | 279 |
How it is read
Names in the registry
- “E/C/F/TAF”, 17 entries
- “TAF”, 12 entries
- “B/F/TAF”, 10 entries
- “F/TAF”, 8 entries
- “B/F/TAF (TOS)”, 4 entries
Conditions, from the studies’ own filings
- Acquired Immunodeficiency Syndrome, 11 studies
- Hepatitis B, Chronic, 10 studies
- HIV Infections, 7 studies
- Hepatitis, 4 studies
- Coinfection, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.